Treatment Approach for MSI-H/dMMR CRC
ASCO 2022 on KEYNOTE-651: Pembrolizumab + mFOLFOX7/FOLFIRI for mCRC: Long-Term Follow-Up of Cohorts B and D
By
ASCO 2022 Conference Coverage
FEATURING
Richard Kim
By
ASCO 2022 Conference Coverage
FEATURING
Richard Kim
Login to view comments.
Click here to Login
Treatment Approach for MSI-H/dMMR CRC